Mah Sing diversification into glove manufacturing on track For representational purposes only. – AFPPIX
PETALING JAYA: Mah Sing Group Bhd’s diversification into glove manufacturing remains on track as it has made progress on physical works for its manufacturing facility and regulatory approvals for the venture.
The group reiterated that the targeted April 2021 production date is on schedule, as the installation of glove dipping lines framework and structure is under way.
It anticipates six production lines to be completed in second-quarter 2021 (Q2’21) with an additional six production lines to be completed in Q3’21, translating to a maximum capacity of up to 3.68 billion pieces of gloves per annum.
PETALING JAYA (Dec 14): S P Setia Bhd clinched the top spot in
The Edge Malaysia Top Property Developers Awards (TPDA) 2020, marking the fifth consecutive year the company won the spot. It dropped to third and fourth positions in 2014 and 2015 respectively, before regaining the title in 2016.
S P Setia president and chief executive officer (CEO) Datuk Khor Chap Jen said the developer is elated to be awarded top honours for the 13th time.
“This would be impossible if not for the strong teamwork we have at Setia. It hasn’t been easy as we have been facing strong headwinds with the soft market and in addition to that, the unprecedented Covid-19 pandemic. No industry has been spared, but our team spirit persevered, and we rose up to overcome the odds by continuing to deliver our best. I would like to dedicate this win to Team Setia,” he added.
Bhd are companies leading the charge in the race to supply the Covid-19 vaccine to 32.7 million Malaysians.
Both have fill and finish facilities that have been approved by the National Pharmaceutical Regulatory Authority (NPRA) and are tipped to handle the supply of vaccines that the government purchases.
The priority list for the government is the frontliners and the elderly who are most at risk. That leaves quite a number of people who would want to be inoculated and likely to seek the vaccine from the private healthcare system.
Seizing the opportunity, there are also a host of companies wanting to bring in vaccines to cater to the private sector. From property developers to engineering companies, most are looking at registering the vaccine with the NPRA and distributing it to the private sector.